Houlihan Lokey Advises Vitruvian Partners

Houlihan Lokey is pleased to announce that Vitruvian Partners (Vitruvian) has completed a majority investment in DeepIntent. The transaction consideration was $637 million, and it closed in September 2025.

Founded in 2016, DeepIntent is a transformational healthcare demand-side platform purpose-built to improve patient outcomes through the integration of real-world data, real-time advertising, and data science. DeepIntent’s proprietary platform, powered by Health Intelligence™, unifies media, clinical data, and AI to drive meaningful engagement between life sciences brands, healthcare providers, and patients. The company’s technology enables marketers to plan, activate, and optimize data-driven campaigns with speed and precision, delivering measurable outcomes, such as audience quality and script lift at scale.

DeepIntent supports campaigns for hundreds of brands, serving 19 of the top 20 global life sciences companies and their agencies, positioning the company as the leading connective software that links premium media with healthcare-specific identity and data assets. With omnichannel capabilities spanning streaming TV, podcasts, point-of-care media, and other high-growth digital channels, DeepIntent sits at the forefront of powerful structural growth drivers, including the rise of personalized, patient-centered healthcare and the growing availability of data and machine learning to enable more relevant and effective engagement.

Vitruvian is a global growth-focused investor with offices in London, Miami, San Francisco, Stockholm, Munich, Madrid, Luxembourg, Mumbai, Singapore, and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has more than $20 billion of active funds, which have backed many global winners and leaders in their sectors.

Houlihan Lokey served as a financial advisor to Vitruvian. This deal highlights Houlihan Lokey’s leading experience in the pharma commercialization space and represents the firm’s 32nd transaction in this sector since 2019.

RELATED: Pharma Services, Mergers & Acquisitions